Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptor…
$1.07+3.88%
报价 2026-11-06
市值
$107.8M
EV
$140M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -80.0%
$0.93$5.35
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CLLSCellectis S.A. | $107.8M | +3.9% | – | 74.7% | – | – | – | |
| FHTXFoghorn Therapeutics Inc. | $111.1M | -1.8% | -18.9% | 42.7% | – | – | – | |
| ANIXAnixa Biosciences, Inc. | $110.4M | +4.8% | -71.7% | 0% | – | – | – | |
| LENZLENZ Therapeutics, Inc. | $110M | +16.3% | -2.6% | 80.2% | – | – | – | |
| AVXLAnavex Life Sciences Corp. | $106.6M | +3.6% | +55.9% | 0% | – | – | – | |
| OTLKOutlook Therapeutics, Inc. | $106.2M | -0.6% | +173.6% | 195.6% | – | – | – | |
| IMUXImmunic, Inc. | $105.7M | +5.9% | -96.9% | 0% | – | – | – | |
| PYXSPyxis Oncology, Inc. | $105.2M | +3.1% | -100.0% | 99.8% | – | – | – | |
| NBPI-Mab | $104.8M | +0.2% | – | 0% | – | – | – | |
| 同行中位数 | – | – | -18.9% | 21.4% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。